What is an inflammatory myofibroblastic tumour?
An inflammatory myofibroblastic tumour (IMT) is a rare soft-tissue tumour made of spindle-shaped cells, called myofibroblasts and fibroblasts, mixed with many inflammatory cells such as plasma cells and lymphocytes.
IMT can grow almost anywhere in the body. The most common sites are the lungs, the abdomen (especially the mesentery, the tissue that holds the bowel in place), the pelvis and retroperitoneum, the bladder and the head and neck.
It mainly affects children, teenagers and young adults, although it can occur at any age. In the past it was often called an “inflammatory pseudotumour”, because it was thought to be a reaction to inflammation rather than a true tumour.
We now know that many IMTs carry gene fusions, most often involving the ALK gene. This discovery has changed treatment, because these fusions can be targeted with drugs (Lovly et al., 2014; Gros et al., 2022).
The World Health Organization classes IMT as an intermediate, rarely metastasising tumour. It can come back after surgery, but it seldom spreads to distant organs (Sbaraglia, Bellan and Dei Tos, 2021).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Intermediate (rarely metastasising) myofibroblastic tumour |
| How common | Rare; one of the more common lung tumours in children |
| Typical age | Mostly children and young adults; can occur at any age |
| Main sites | Lung, abdomen and mesentery, pelvis, bladder, head and neck |
| Key symptoms | Depend on site; fever, weight loss and tiredness in some |
| Gene changes | ALK fusions in about half; ROS1, NTRK3, PDGFRB or RET in many others |
| Main treatment | Complete surgical removal; ALK or other targeted drugs if surgery is not possible |
| Outlook | Usually very good; local recurrence in some; distant spread is rare |
2. Types of IMT
| Type | Description |
|---|---|
| Classic IMT | Spindle cells with inflammation; the most common form |
| ALK-positive IMT | Carries an ALK fusion; more common in children and young adults |
| ALK-negative IMT | Often carries ROS1, NTRK3, PDGFRB or RET fusions; more common in adults |
| Epithelioid inflammatory myofibroblastic sarcoma (EIMS) | An aggressive variant, usually in the abdomen, with rounded cells and a RANBP2-ALK or RRBP1-ALK fusion (Marino-Enriquez et al., 2011) |
By site
| Site | Notes |
|---|---|
| Lung | Often a single, well-defined nodule; may be found by chance |
| Abdomen and mesentery | Can grow large; higher risk of recurrence |
| Bladder | Causes blood in the urine |
| Head and neck | Sinuses, eye socket, throat or larynx |
| Other | Liver, stomach, bowel, heart, brain and limbs, rarely |
3. Causes and risk factors
The cause of IMT is not fully understood. In many tumours, two genes have broken and joined together to form a fusion gene. The fusion produces an abnormal, permanently switched-on signalling protein that drives cell growth.
| Gene fusion | Approximate frequency | Notes |
|---|---|---|
| ALK | About 50-60% | Most common in children; seen as ALK protein on staining |
| ROS1 | About 5-10% | Often in young children (Hornick et al., 2015) |
| NTRK3 (ETV6-NTRK3) | A small number | Can be treated with TRK inhibitors |
| PDGFRB and RET | Rare | Found in some ALK-negative tumours (Lovly et al., 2014) |
These fusions arise by chance in the tumour cells. They are not inherited. Earlier ideas that IMT is caused by infection or injury have not been proven.
4. How does it look
On scans
| Feature | Description |
|---|---|
| Shape | A solid mass, usually with fairly clear edges |
| Size | From a few centimetres to large masses over 10 cm, especially in the abdomen |
| Lung IMT | A single round nodule or mass, sometimes with calcium |
| Enhancement | Takes up contrast on CT or MRI |
| PET-CT | Often bright, because the tumour is active and inflamed |
On scans, IMT can look like other cancers, so a biopsy or surgical removal is needed to make the diagnosis.
To the surgeon
When removed, IMT is usually a firm, white or tan mass, sometimes with a whorled cut surface. It may stick to nearby organs.
Under the microscope
| Feature | Description |
|---|---|
| Spindle cells | Long, thin cells arranged in bundles or loose patterns |
| Inflammatory cells | Many plasma cells, lymphocytes and sometimes eosinophils |
| Background | Can be loose and gel-like, densely cellular or scar-like |
| ALK staining | Positive in ALK-rearranged tumours (Coffin, Hornick and Fletcher, 2007) |
| Other stains | Smooth muscle actin is often positive; ROS1 or pan-TRK stains in other fusion types |
Visible signs
Most IMTs are deep inside the body and cannot be seen. A tumour in the head and neck or a limb may be visible as a swelling. Children with large abdominal tumours may have a swollen tummy, and some look pale and unwell because of anaemia.
5. Symptoms
Symptoms depend on where the tumour grows. Some people have no symptoms at all.
Symptoms by site
| Site | Possible symptoms |
|---|---|
| Lung | Cough, chest pain, breathlessness, coughing up blood, repeated chest infections |
| Abdomen | Pain, a lump, swelling, feeling full, bowel blockage |
| Bladder | Blood in the urine, pain when passing urine, needing to go often |
| Sinuses and nose | Blocked nose, facial pain or swelling |
| Eye socket | Bulging eye, double vision |
| Throat or larynx | Hoarse voice, noisy breathing or difficulty swallowing |
General symptoms
About a quarter to a third of people have general symptoms caused by inflammatory signals released by the tumour:
- Fever
- Weight loss
- Tiredness and feeling generally unwell
- Night sweats
Blood tests may show anaemia, a high platelet count, a raised ESR or CRP and high antibody levels. These often return to normal after the tumour is removed.
When to seek medical advice
See a doctor if you or your child has a lump, unexplained fever or weight loss, a cough that does not go away, or blood in the urine.
Seek urgent help for severe abdominal pain with vomiting, coughing up a lot of blood or difficulty breathing.
6. Diagnosis
| Test | Purpose |
|---|---|
| Ultrasound, CT or MRI | Shows the size and position of the mass |
| PET-CT | Helps with staging and checking response |
| Biopsy or surgical removal | Confirms the diagnosis |
| Immunohistochemistry | ALK, ROS1, pan-TRK and smooth muscle markers |
| Molecular testing (FISH or RNA sequencing) | Identifies the fusion gene |
| Blood tests | Blood count, inflammatory markers and general health |
| Cystoscopy | For suspected bladder IMT |
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Sarcomas | Other spindle-cell cancers with different markers and fusions |
| IgG4-related disease | Inflammatory condition with many IgG4 plasma cells, no ALK fusion |
| Infection or abscess | Organisms found; improves with antibiotics |
| Lymphoma | Abnormal lymphocytes rather than spindle cells |
| Gastrointestinal stromal tumour | KIT- or DOG1-positive |
7. Treatment
IMT is treated by a specialist sarcoma or paediatric oncology team.
Surgery
Complete surgical removal with a clear margin is the main treatment and often cures the tumour. Surgeons try to remove the whole tumour while protecting nearby organs.
Targeted drugs
| Fusion | Drugs |
|---|---|
| ALK | Crizotinib (approved for ALK-positive IMT that cannot be removed), ceritinib, alectinib, lorlatinib |
| ROS1 | Crizotinib, entrectinib |
| NTRK | Larotrectinib, entrectinib |
| Others | Clinical trials of targeted drugs |
Crizotinib produced responses in most people with ALK-positive IMT in clinical trials, in children and adults (Butrynski et al., 2010; Mosse et al., 2017; Schoffski et al., 2021). These drugs can be used before surgery to shrink a tumour that would otherwise need a very large operation, or as the main treatment if surgery is not possible.
Other treatments
| Treatment | When it is used |
|---|---|
| Chemotherapy | Methotrexate with vinblastine or vinorelbine, or anthracycline-based combinations, when targeted drugs are not suitable |
| Anti-inflammatory medicines | NSAIDs or steroids may shrink some tumours |
| Radiotherapy | Occasionally, when other options are limited |
| Watchful waiting | Rarely, for small tumours after incomplete removal, with close monitoring |
Side effects of targeted drugs
| Side effect | Notes |
|---|---|
| Nausea and diarrhoea | Common, usually mild |
| Visual disturbances | Brief light trails or flashes with crizotinib |
| Swelling | Ankles or face |
| Raised liver tests | Checked with regular blood tests |
| Low blood counts | Monitored during treatment |
IMT in children
IMT is one of the more common lung tumours in children, and it also occurs in the abdomen, bladder and head and neck. Children are more likely than adults to have an ALK-positive tumour, and very young children may have ROS1 or NTRK fusions.
Treatment plans for children aim to cure the tumour while avoiding long-term harm. If a tumour can only be removed by a mutilating operation, for example one that would remove a whole lung or the bladder, doctors may first give an ALK or other targeted drug to shrink it. Surgery then becomes smaller and safer.
Most children with IMT go on to live normal, healthy lives after treatment.
IMT in adults
In adults, IMT is more often ALK-negative and may be found in the lung, abdomen or other sites. Molecular testing is especially important in adults, because finding a ROS1, NTRK, RET or PDGFRB fusion can offer a targeted treatment option if the tumour cannot be removed.
8. Outlook (prognosis)
The outlook for most people with IMT is very good, especially after complete removal.
| Situation | Outlook |
|---|---|
| Completely removed lung IMT | Excellent; recurrence is uncommon |
| Abdominal or pelvic IMT | Higher risk of local recurrence, around a quarter of cases |
| ALK-positive IMT that cannot be removed | Often controlled well with ALK inhibitors |
| Distant spread | Rare, under 5% |
| Epithelioid inflammatory myofibroblastic sarcoma | More aggressive; poorer outlook, although ALK inhibitors can help |
If the tumour comes back, it can often be removed again or treated with targeted drugs.
9. Follow-up
| Time after treatment | Typical follow-up |
|---|---|
| First 2-3 years | Check-ups and scans every 3-6 months |
| Later | Less frequent scans, often for 5 years or more |
| On targeted drugs | Regular blood tests, heart tests and eye checks |
10. Living with IMT
- Ask for treatment in a sarcoma or paediatric oncology centre
- Ask whether fusion testing has been done, because it opens the door to targeted drugs
- Keep all follow-up appointments, as recurrence can be treated more easily when found early
- Report new symptoms, such as fever, pain or a new lump, between visits
- Seek support from sarcoma charities and patient groups
- Help children stay at school, with support from the hospital school team
- Keep a copy of your pathology report, including the fusion result, in case you need treatment elsewhere in the future
- Ask about side-effect plans before starting a targeted drug, so you know which symptoms to report
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is IMT cancer? | It is a tumour of intermediate behaviour: it can grow and come back, but it rarely spreads |
| Is it the same as an inflammatory pseudotumour? | That is an older term; many lesions once called pseudotumours are now known to be IMTs |
| Is IMT inherited? | No |
| Will my child need chemotherapy? | Usually not; surgery alone is often enough, and targeted drugs are used if needed |
| Can it come back? | Yes, especially in the abdomen, which is why regular scans are important |
| How long are targeted drugs taken? | It varies; some people take them for months before surgery, others for longer if the tumour cannot be removed |
| Can IMT occur during pregnancy? | Rarely; treatment is planned by a specialist team to protect both mother and baby |
| What is an ALK inhibitor? | A tablet that blocks the abnormal ALK protein driving the tumour |
12. Questions to ask your care team
- Where exactly is the tumour, and can it be completely removed?
- Does the tumour have an ALK, ROS1 or NTRK fusion?
- Would a targeted drug before surgery help?
- What is the risk of the tumour coming back?
- How often will we need scans?
- Are there clinical trials available?
Resources
- Butrynski, J.E. et al. (2010) ‘Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor’, New England Journal of Medicine, 363(18), pp. 1727-1733.
- Coffin, C.M., Hornick, J.L. and Fletcher, C.D. (2007) ‘Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases’, American Journal of Surgical Pathology, 31(4), pp. 509-520.
- Gros, L. et al. (2022) ‘Inflammatory myofibroblastic tumour: state of the art’, Cancers, 14(15), 3662.
- Hornick, J.L. et al. (2015) ‘Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors’, Modern Pathology, 28(5), pp. 732-739.
- Lovly, C.M. et al. (2014) ‘Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions’, Cancer Discovery, 4(8), pp. 889-895.
- Marino-Enriquez, A. et al. (2011) ‘Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK’, American Journal of Surgical Pathology, 35(1), pp. 135-144.
- Mosse, Y.P. et al. (2017) ‘Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group study’, Journal of Clinical Oncology, 35(28), pp. 3215-3221.
- Sbaraglia, M., Bellan, E. and Dei Tos, A.P. (2021) ‘The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives’, Pathologica, 113(2), pp. 70-84.
- Schoffski, P. et al. (2021) ‘Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE’, European Journal of Cancer, 156, pp. 12-23.
- National Cancer Institute (2026) Inflammatory Myofibroblastic Tumor. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/inflammatory-myofibroblastic-tumor (Accessed: October 2026).
Prepared by the editorial team, October 2026.